What an FDA Inspection History Tells You About an API Supplier

An FDA inspection history shows you how consistently a site has met the FDA’s manufacturing standards over time. It can also warn you early if that site might delay your own drug approval. Yet many buyers check only the latest inspection result and move on.

That shortcut can miss a site whose standards are slowly slipping. Or it can let one old problem overshadow years of steady progress.

The fuller picture comes from reading every inspection together. This shows whether issues were fixed for good and whether the FDA still has unresolved concerns. Buyers can then look at the daily quality habits behind that record.

What Does an FDA Inspection Record Show About an API Supplier?

An FDA inspection record shows how well an API supplier controls quality during FDA inspections. It reveals where the supplier’s systems fell short and how it responded. Each document in the record points to something specific about the supplier.

Here is what each part of the record tells you about the supplier:

  • Inspection classification: Every inspection ends with one of three outcomes. An NAI ("no action indicated") outcome means the supplier’s operations held up well under inspection. A VAI ("voluntary action indicated") outcome means inspectors found problems that the supplier can fix on its own. An OAI ("official action indicated") outcome points to serious lapses in how the supplier controls quality.
  • Form 483: Inspectors issue this form at the end of a visit to list what they observed. It shows the supplier’s specific weak spots, such as poor record-keeping or unclear cleaning procedures. The supplier’s written reply shows how seriously it treats those problems.
  • Warning letter: The FDA issues this letter when violations are significant. It often means the supplier did not fix serious problems to the FDA’s satisfaction.
  • Import alert: FDA uses this for suppliers outside the U.S. It means FDA has concerns serious enough to stop the supplier’s products at the border. The FDA can detain them without examining them first, which can halt your supply until the alert is lifted.

Most of these records are publicly available on the FDA’s website. Form 483s are published less often, so ask the supplier for copies along with its responses.

Why Does the Pattern Matter More Than a Single Inspection Outcome?

The pattern matters more because a single inspection covers only a few days of a supplier’s work. Several inspections show whether quality holds up over the years. For anyone assessing an API manufacturing partner, that long view is the better guide to future performance.

FDA’s FY2025 Report on the State of Pharmaceutical Quality covered 1,309 inspections. Only 22% ended as NAI, while 60% ended as VAI. The remaining 18% were classified as OAI. Since VAI is the most common outcome, one VAI result does little to set an API supplier apart. Here are three things to check across visits:

Repeat observations signal fixes that did not work

Check whether the same 483 observations appeared on more than one visit. A repeat usually means the supplier corrected what inspectors saw but missed the cause. An API supplier that resolves the cause rarely sees that observation return.

The trend across visits outweighs any one result

Next, check which way classifications move over time. Movement from OAI toward NAI suggests lasting improvement. A slip from NAI to VAI, with more observations each visit, points to a quality system under strain.

Inspection type and recency change the weight of a finding

Finally, weigh each result by what the visit covered and when it happened. A pre-approval inspection checks readiness to make one product. A routine visit reviews the whole quality system, so it says more about the supplier overall. An older result may no longer reflect how the supplier works today.

What Else Should You Assess Before Trusting an API Supplier’s Inspection Record?

Before trusting the record, check the everyday quality work that sits behind it. The inspection record tells you what the FDA found. The supplier’s own systems show how it keeps quality steady day to day.

This matters more since May 2025, when the FDA announced expanded unannounced inspections at foreign manufacturing facilities. With less notice, the supplier has little time to prepare before a visit. Its routine standards are what inspectors will see.

Here are five areas to review during due diligence:

  • Control over process changes: Ask how the supplier handles changes to equipment or raw materials. Each change should be assessed and approved before it reaches production. Unmanaged changes can shift impurity levels without anyone noticing.
  • Oversight of its own vendors: The supplier depends on outside vendors for starting materials. Ask how it approves those vendors and tests incoming batches. Relying only on a vendor’s certificate of analysis leaves room for error.
  • Protection of data: Ask how the supplier controls who can create or change electronic records. Every change should be logged automatically and reviewed by the quality team.
  • Authority of the quality team: The supplier’s quality team should be able to reject a batch or stop production without pressure.
  • Results from other regulators: EMA and PMDA inspect against their own standards. Steady results across agencies make the FDA record more believable.

When these checks match a steady inspection record, you can trust that API supplier with more confidence.

FAQs

How can an API supplier’s inspection history affect your own approval timeline?

An API supplier’s inspection history can delay your approval if the FDA has open concerns about its site. The FDA may hold your application until those concerns are resolved. This is called a facility withhold.

Where can you check an API supplier’s FDA inspection history?

You can check a supplier’s FDA inspection history on the FDA’s public websites. Most records can be searched free of charge by company or site name.

Here is where to find each type of record:

  • FDA Data Dashboard: Inspection classifications and summaries of cited observations.
  • Warning Letters page: The full text of letters the FDA has issued.
  • Import Alerts page: Sites whose products the FDA can currently detain at the border.

Search under the site’s legal name, which may differ from its trading name.

How often does the FDA inspect an api manufacturing site?

FDA decides how often to inspect an API manufacturing site using a risk-based model. No single fixed interval applies to every site. The model weighs a site’s compliance history and the time since its last inspection. The type of product made there also counts. A site with a poor record or no recent visit is more likely to be chosen.

Is an API site with no FDA inspection history riskier to use?

A site with no FDA inspection history brings more uncertainty to your filing. The FDA considers sites without prior on-site inspections to be higher risk during application review.

As a result, FDA may schedule a pre-approval inspection before deciding on your application. Your approval then depends partly on how that first visit goes. Running your own detailed audit before filing can reduce this uncertainty.